Illumina, Inc. Hits New 52-Week High of $158.78, Up 48.7%

Illumina, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 158.78 on May 28, 2026. This achievement underscores the company's robust performance over the past year, with a remarkable increase of 48.7%, significantly outpacing the S&P 500's growth of 28.45% during the same period. With a market capitalization of USD 22,890 million, Illumina operates as a mid-cap company, reflecting its substantial presence in the industry. The stock's price-to-earnings (P/E) ratio stands at 36.00, indicating investor confidence in its earnings potential. Additionally, the company maintains a low debt-to-equity ratio of 0.16, suggesting a strong balance sheet and financial stability. Illumina's return on equity is an impressive 23.44%, highlighting its efficiency in generating profits from shareholders' equity. However, the company does not currently offer a dividend, as indicated by a dividend yield of 0.00%. The stock's price-to-book ratio is 8.41, further illustrating its valuation in the market. Overall, Illumina's recent performance reflects its strong position within the biotechnology landscape.